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Neuroendocrine lung tumors comprise 4 categories of tumors de-
scribed in the WHO 1999 (1) and 2004 classiﬁcation (2) along with 
3 different grades: small cell lung carcinoma (SCLC) and large cell 
neuroendocrine carcinoma (LCNEC) are 2 high grade lung tumors. 
Carcinoids have 2 subtypes: the typical carcinoids a low grade tumor 
and atypical carcinoids an intermediate grade tumor. This subset of 
tumors shares morphological, ultrastructural, immunohistochemical 
and molecular characteristics but probably derive from 2 different stem 
cells. Although it appears as a spectrum of high grade less differenti-
ated to well differentiated neuroendocrine tumors, it has been shown 
for long that they likely belong to 2 categories with 2 different stem 
cells and it is also believed that they originate from 2 different stem 
cells. SCLC and LCNEC display neuroendocrine features have a high 
rate of proliferation, high clinical agressivity and metastatic potential. 
They are probably derived of a common lung cancer stem cells. There 
is no preinvasive lesion identiﬁed for the high grade neuroendocrine 
tumors SCLC and LCNEC. In contrast, carcinoids typical and atypical, 
have an indolent or intermediate clinical course and likely derive from 
each others, atypical showing nests of proliferation inside an otherwise 
wide typical carcinoid, it is likely that atypical carcinoids derive from 
progression of typical carcinoids. A precursor lesion identiﬁed for car-
cinoids is the diffuse idiopathic pulmonary neuroendocrine hyperplasia 
(DIPNECH) which is not a preneoplastic lesion. SCLC is the most 
frequent neuroendocrine tumor accounting for 20-25 % of lung cancer, 
but all others are rare not exceeding 7 % all together.
The molecular signature of cell differentiation
These phenotypic traits constitute immunohistochemical features that 
allow positive and differential diagnosis of SCLC and other neuroendo-
crine tumors. A common signature between all these is the expression 
of speciﬁc neuroendocrine markers. To this level since all 4 entities 
disclose neuroendocrine markers at about the same level, these could 
not be considered as a grading of differentiation but as a constant trait 
linking them. Chromogranin, synaptophysin, CD56/NCAM are the 
3 speciﬁc neuroendocrine markers allowing their recognition from 
NSCLC, but not from each other. SCLC has a high rate of mitosis and 
proliferation with 20 to 100 mitosis for 10 high power ﬁeld and a Ki-67 
proliferative index exceeding 50 % of positive tumor cells. In the same 
way, LCNEC has high rate of proliferation and both have large areas 
of necrosis. Their apoptotic levels are as high as expected from high 
proliferation rate and high cell turnover. In contrast, carcinoid tumors 
are characterized by organoid growth pattern dysplaying more achieved 
neuroendocrine differentiation than SCLC, the same level of differen-
tiation than LCNEC but are characterized by a lower mitotic rate (3).
TTF-1 is only expressed in the 2 high grade neuroendocrine prolifera-
tions in 85 % of SCLC and 50 % of LCNEC but usually not in carci-
noids (a few atypical carcinoids has been reported for TTF-1 expres-
sion). This difference otherwise reﬂects the two different stem cell for 
high grade neuroendocrine tumor arising from a typical lung stem cell 
and the carcinoids (a predestined neuroendocrine cell) (4).
The molecular genetic alteration reﬂecting proliferation and progres-
sion, chromosomal imbalances, P53 pathway alterations, Rb inactiva-
tion (5) and a Fas and FasL deregulation are characteristic of high grade 
neuroendocrine tumors, SCLC and LCNEC. Alteration of upstream 
regulators of P53, P14ARF and Mdm2 are frequent in SCLC and LCNEC 
but rare in carcinoids. E2F1 overexpression (6), a high frequency of 
P53 mutation and overexpression (80 % and 70 % respectively), the 
deregulation of Bcl2:Bax ratio in favor of Bcl2 (7), a downregulation of 
Fas with upregulation of its ligand FasL (8) and 95 % frequency of Rb 
inactivation (9) are characteristics of high grade neuroendocrine tumors.
Upstream regulator of P53, P14ARF, and one of its inducing factor 
E2F1are characteristically lost or gained respectively in high grade neu-
roendocrine tumors with 50 % los of P14ARF (10) and 90 % overexpres-
sion of E2F1 (6) are characteristic of SCLC and LCNEC. In contrast, a 
common frequency of 30 % of Mdm2 overexpression is observed in all 
neuroendocrine tumors and NSCLC. P14ARF plays independent role of 
P53 in G2 arrest and apoptosis, in response to both oncogenic stimuli 
and DNA damage (11-13).
Cell immortalization by telomerase is an almost constant features in 
SCLC and LCNEC and unconspicuous in carcinoids.
In regard with the E-cadherin intercellular adhesion membrane, E-
catenin complex protein, E-cadherin and β-catenin loss or impaired 
expression (cytoplasmic versus membranar) was observed with a higher 
frequency in high grade neuroendocrine tumors (90 %) than in NSCLC 
and in carcinoids, 30 % of which have loss or cytoplasmic delocaliza-
tion of E-cadherin or β-catenin. E-cadherin impairment expression was 
correlated with extensive disease in typical and atypical carcinoids (14).
The Sonic Hedge-hog pathway (SHh) with its receptor Patch is char-
acteristic of neuroendocrine differentiation but is strongly activated 
in SCLC and involved in the maintenance of its malignant phenotype. 
There was no study of SHh pathway in carcinoid tumors.
Human Acute Homolog 1 (ASH1) a transcription factor known to play 
a crucial role in neuronal endocrine determination and differentiation is 
expressed at high level and uniformly in classic SCLC and in NSCLC 
with neuroendocrine features. It has been shown to be absent in dif-
ferentiated typical carcinoids, although it was expressed in atypical 
carcinoids, LCNEC and SCLC, such imitating its early and transient 
expression pattern during development but not being necessary for 
the maintenance of neuroendocrine phenotype as it is absent typical 
carcinoids.
The tyrosine-kinase growth factors and receptors are involved in the 
oncogenesis of SCLC where kit receptor encoded by the c-kit gene 
(homologous with PDGF) is overexpressed in about 50 % of SCLC. 
It is also overexpressed in 63 % of LCNEC as was PDGRα. Met the 
product of the proto-oncogene c-met is aberrantly overexpressed in 
high grade neuroendocrine tumors, SCLC and LCNEC. Aberrant met 
activations through binding to its high afﬁnity ligands HGF (scatter 
factor) provokes activation of multiple signal transductors of the tyro-
sine-kinase pathway. Interestingly Met was the only prognostic factor 
in LCNEC with Met expression and was signiﬁcantly correlated with 
overall survival (p=0.03) (15). Although no mutation was observed 
in Met or RTK in positive LCNEC, Met mutation have been found in 
SCLC prompting clinical investigation for the therapeutic effect of 
RTK inhibitors targeting c-met in SCLC. 
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The verb “salvage”, according to Oxford Dictionary, is to save property 
from shipwreck, ﬁre or war, implying maximization of beneﬁt in a 
relatively hopeless situation. “Salvage therapy” carries a similar mean-
ing of being a therapy with remote hope of beneﬁt. Patient should be 
in a medical condition that is beyond cure or survival prolongation and 
therapy may only help in a small portion of patients. Stage IIIB and IV 
non-small-cell lung cancer (NSCLC) is not a curable condition at diag-
nosis, however, ﬁrst line systemic chemotherapy offers a good chance 
of survival prolongation and improvement of quality of life.(1-2) Plati-
num-based doublet with a third generation cytotoxic drug such as gem-
citabine, paclitaxel, vinorelbine or docetaxel is an universally accepted 
standard therapy. Upon treatment failure to ﬁrst line therapy a number 
of approved second line therapies including docetaxel, pemetrexed, 
erlotinib and geﬁtinib are now available. Single agent docetaxel at 
75mg/m2 every 3 weeks can attain tumor response rate of less than 10% 
but the median survival of 7.5 months which was statistically higher 
than the 4.6 months in the best supportive care group.(3) Pemetrexed 
was approved in 2004 when Hanna et al demonstrated in a randomized 
study showing that the medians survival of pemetrexed to be similar to 
docetaxel as second line therapy (8.3 months and 7.9 months, respec-
tively).(4) Therefore second line chemotherapy is now considered to be 
standard treatment rather than “salvage therapy”. Erlotinib is an epider-
mal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) that 
was shown in a randomized comparative study to attain survival beneﬁt 
for patients who failed one or more line of chemotherapy. This pivotal 
study (BR-21) reported median survival of 6.7 months versus 4.7 
months in erlotinib and placebo group respectively.(5) Geﬁtnib shares 
similar mechanism of action but its survival outcomes in a randomized 
phase III study (ISEL)failed to reach signiﬁcant statistic endpoint.(6) In 
the subgroup analysis ISEL survival beneﬁt was reported in non-smok-
er, adenocarcinoma and patients of Asian decent. 
For the beneﬁt of this session, we deﬁne salvage therapy as treatment 
from 3rd line onward or therapy for situation with no established 
survival beneﬁt. This would include salvage therapy for failure to sec-
ond-line chemotherapy, salvage therapy for EFGR-TKI resistance and 
salvage therapy for brain metastasis after failing whole brain radiother-
apy (WBRT). We shall examine some of the early data and try to judge 
if their potential toxicity is worthy of their limited efﬁcacy. 
Salvage therapy for failure to second-line chemotherapy 
Massarelli et al (7) examined the outcomes of third/fourth line therapy 
in a retrospective study. They reviewed 700 patient records and identi-
ﬁed 43 patients who had received third/fourth line therapy after failing 
platinum-based doublet and docetaxel. Tumor response rate declined 
with each line of chemotherapy: ﬁrst line, 20.9%; second line 16.3
%; third line, 2.3%; and fourth line, 0%. Median overall survival was 
16.4 months from the date of diagnosis but only 4 months from third/
fourth line chemotherapy. The ﬁnding suggested that chemotherapy 
beyond second line has limited efﬁcacy. However, this study is limited 
by selecting patients who has failed with disease progression or toxicity 
within 90 days of prior treatment. We cannot deny that patients with a 
durable response to ﬁrst line chemotherapy may have potential beneﬁt 
from re-challenge with chemotherapy. Clinical trial on this subgroup of 
patient is lacking. Thus a better approach to patients who failed 2 line 
of chemotherapy is biologic therapy such as erlotinib or geﬁtinib.(5-6) 
It is known that somatic mutation at EGFR explains the dramatic clini-
cal responsiveness to EGFR-TKI.(8,9) Shigematsu et al (10) identiﬁed 
a signiﬁcant difference in incidence between gender (female 42% vs 
male 14%, p<0.01), ethnicity (Asian 30% vs non-Asian 8%), smok-
ing status (never smoker 51% versus 10% ex- or ongoing smoker) and 
histology (adencocarinocma 40% vs other histology <3%). In Asia the 
histologic subtype of adenocarcinoma was found to be the strongest 
predictor of EGFR mutation.(11) Therefore the salvage therapy for pa-
tients with adenocarcinoma after failing 2 lines of chemotherapy should 
be EGFR TKI. 
The role of anti-angiogenesis in combination with chemotherapy in 
third/fourth line has not been well deﬁned. Two randomized stud-
ies have shown that the combination of bevacizumab (a monoclonal 
antibody against the ligand of circulating VEGF) and doublet chemo-
therapy has additional beneﬁt over standard ﬁrst line platinum-based 
combination.(12) Use of single agent bevacizumab in second/third line 
has limited efﬁcacy. Addition of bevacizumab to second line single 
agent chemotherapy was studied in a randomized phase II study (13) 
that reported a trend towards improvement with the combination. A 
phase III study is ongoing.
Salvage therapy for EGFR TKI resistance
EGFR activation triggers downstream signaling that sustains cell 
survival and proliferation. TKI of the EGFR targets the ATP-binding 
domain and results in suppression of tumor growth. Most patients who 
